US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

39.67

-0.4100-1.02%

Volume:143.91K

Turnover:5.68M

Market Cap:247.94M

PE:- -

High:39.84

Open:39.76

Low:39.00

Close:40.08

52wk High:40.86

52wk Low:22.12

Shares:6.25M

Float Shares:6.25M

Volume Ratio:1.29

T/O Rate:2.30%

Dividend:0.28

Dividend Rate:0.71%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Brookdale Senior Living (BKD) and Legend Biotech (LEGN)

Vertex 1Q Net Y772.00m vs Net Y658.00m

Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Twist Bioscience Director Robert Chess Disposes of Common Shares Worth $2.041.010,13

Tango Falls After Wider-than-Expected Quarterly Loss

Jefferies Remains a Buy on Vertex Pharmaceuticals (VRTX)

U.S. Stocks on the MOVE-Duke Energy, Sea, Cardinal Health

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO)

Vertex Pharmaceuticals Incorporated : Bofa Global Research Adds Stock to Its US 1 List

THOMSON REUTERS

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

Press Release: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

Press Release: Theriva(TM) Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

Truist Raises Revolution Medicines PT on Lung Cancer Pipeline Potential

Press Release: Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Press Release: Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/IDNA/news?page=12"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":39.67,"timestamp":1787601600000,"preClose":40.08,"halted":0,"volume":143908,"delay":0,"changeRate":-0.010229540918163587,"floatShares":6250000,"shares":6250000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.41,"latestTime":"08-25 07:02:11 EDT","open":39.76,"high":39.84,"low":39,"amount":5676438.10828,"amplitude":0.020958,"askPrice":43.74,"askSize":100,"bidPrice":35.67,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":39.67,"sharesOutstanding":5100000,"nav":40.06069,"aum":250379312.5,"dividendRate":0.007101,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.67,"preClose":39.67,"latestTime":"19:30 EDT","volume":58,"amount":2282.47,"timestamp":1787614204422,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.289403465846127,"impliedVol":0.0476,"impliedVolPercentile":0.016},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6250000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.289403465846127,"shares":6250000,"dividePrice":0.2817,"high":39.84,"amplitude":0.020958,"preClose":40.08,"low":39,"week52Low":22.12,"pbRate":"--","week52High":40.8599,"institutionHeld":0,"latestPrice":39.67,"eps":0,"divideRate":0.007101,"volume":143908,"delay":0,"ttmEps":0,"open":39.76,"prevYearClose":26.19,"prevWeekClose":40.08,"prevMonthClose":32.33,"prevQuarterClose":33.75,"fiveDayClose":35.86,"twentyDayClose":32.24,"sixtyDayClose":30.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:12,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658089139","title":"Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658089139","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658089139?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Socie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343572/0/en/avalyn-reports-second-quarter-2026-financial-results-and-recent-business-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","HYLG","NVIB","IDNA","FVC","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658390895","title":"Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658390895","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658390895?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343555/14025/en/arbutus-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","GDOC","HYLG","IDNA","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974863","title":"Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Brookdale Senior Living (BKD) and Legend Biotech (LEGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974863?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:10","pubTimestamp":1786533037,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vertex Pharmaceuticals (VRTX), Brookdale Senior Livi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-brookdale-senior-living-bkd-and-legend-biotech-legn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-brookdale-senior-living-bkd-and-legend-biotech-legn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4185","BK4588","PBE","LU1430594728.SGD","IBBQ","BBH","IE0002270589.USD","XLV","XBI","LU0061475181.USD","IE00B19Z3581.USD","LU0234570918.USD","LABU","VERX","BK4505","LU2237438978.USD","CANC","LU0757428866.USD","IE00B19Z3B42.SGD","LU2417539215.USD","LU0079474960.USD","LU1815336091.USD","BKD","SG9999001176.SGD","LU0432979614.USD","LU1035775433.USD","LU1778281490.HKD","LU0058720904.USD","IE00B894F039.SGD","SG9999001176.USD","VRTX","LU0029874061.USD","TBXU","LU0417517546.SGD","LU2089984988.USD","IDNA","LU1499592464.USD","LU1674673691.USD","LEGN","MEMS","IE00BZ9MQY76.HKD","IBB","HCSG","BK4532","GNMX","LU2462157665.USD","LU2468319806.SGD","MEDI","BIB","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658414920","title":"Vertex 1Q Net Y772.00m vs Net Y658.00m","url":"https://stock-news.laohu8.com/highlight/detail?id=2658414920","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658414920?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:41","pubTimestamp":1786524060,"startTime":"0","endTime":"0","summary":"Results are based on Japanese accounting standards.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU0289739699.SGD","IBB","LU1093756325.SGD","LU2362541513.USD","SG9999001176.SGD","TBXU","LU1430594728.SGD","IE00B19Z9P08.USD","LU1674673428.USD","LU1815336091.USD","SGXZ57979304.SGD","BK4023","VERX","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","IE0002141913.USD","LU2456880835.USD","BIB","IE00B4R5TH58.HKD","IE0009355771.USD","LU0432979614.USD","LU2089984988.USD","LU0566484027.USD","BBH","LU0234570918.USD","IE00BZ9MQY76.HKD","SG9999013999.USD","PBE","VRTX","BK4585","LU0757428866.USD","LU0256863811.USD","GNMX","LU0058720904.USD","IBBQ","LU2462157665.USD","LU0079474960.USD","IE00B19Z9Z06.USD","LU2237438978.USD","IE00B894F039.SGD","BK4588","LU0823416689.USD","SG9999001176.USD","BK4567","LU1674673691.USD","IDNA","LU1035775433.USD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MEDX","NVIB","IND","HYLG","GDOC","AARD","BK4007","BMED","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658419948","title":"Twist Bioscience Director Robert Chess Disposes of Common Shares Worth $2.041.010,13","url":"https://stock-news.laohu8.com/highlight/detail?id=2658419948","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658419948?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:06","pubTimestamp":1786478789,"startTime":"0","endTime":"0","summary":"Twist Bioscience Director Robert Chess disposes of common shares worth $2.041.010,13Direktur Robert Chess mengeksekusi opsi, memperoleh 18.417 saham Twist Bioscience pada harga USD 11,89 per saham.Pad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL7QKKdC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Twist Bioscience Director Robert Chess Disposes of Common Shares Worth $2.041.010,13","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","BK4588","GNOM","BK4139","IDNA","ARKG","TWST","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658115349","title":"Tango Falls After Wider-than-Expected Quarterly Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658115349","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658115349?lang=en_us&edition=fundamental","pubTime":"2026-08-11 23:18","pubTimestamp":1786461505,"startTime":"0","endTime":"0","summary":"BUZZ-Tango falls after wider-than-expected quarterly loss** Shares of drug developer Tango TherapeuticsTNGX.Ofall 3.3% to $26.75** Co reportsQ2 lossof 37 cents/share, vs. analysts' average loss estima","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4N44814E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948897.HKD","BBH","MEDI","IBBQ","IDNA","LU0320765992.SGD","PTH","LU1674673428.USD","LU1778281490.HKD","TBXU","IE00B7SZLL34.SGD","BMED","IE00BJJMRZ35.SGD","IE00BZ1G4Q59.USD","LU0889565916.HKD","LU1066053197.SGD","LU2468319806.SGD","BIB","IE0002270589.USD","TNGX","LU0234570918.USD","IE00B2B36J28.USD","LU2087621335.USD","RVMD","LU0861579265.USD","IE0009355771.USD","BK4588","IE00B4R5TH58.HKD","SG9999015952.SGD","BK4585","LU0965509010.AUD","LU0965508806.USD","LU1934455863.HKD","LU2089984988.USD","BK4583","LU0289739699.SGD","LU1674673691.USD","IE00BJT1NW94.SGD","BK4532","LU1066051498.USD","CANC","GILD","LU1934455277.USD","LU0114720955.EUR","IBB","BK4139","LU2324357040.USD","IE00B19Z3581.USD","LU0109394709.USD","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919006","title":"Jefferies Remains a Buy on Vertex Pharmaceuticals (VRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658919006?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:56","pubTimestamp":1786460205,"startTime":"0","endTime":"0","summary":"Jefferies analyst Akash Tewari maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $633.00. According to TipRanks, Te...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0256863811.USD","LU0432979614.USD","LU2237438978.USD","IE00B19Z9P08.USD","BK4139","IE00B19Z3B42.SGD","IE00B19Z3581.USD","PBE","SGXZ57979304.SGD","IBB","LU0889565916.HKD","LU0289739699.SGD","LU2236285917.USD","LU0757428866.USD","LU2089984988.USD","BK4023","IE00BFTCPJ56.SGD","TBXU","IE00B894F039.SGD","LU0058720904.USD","IE0002141913.USD","BIB","IBBQ","IE00B2B36J28.USD","LU2417539215.USD","LU2362541513.USD","BBH","LU1778281490.HKD","LU0320765992.SGD","LU1815336091.USD","LU2468319806.SGD","BK4585","IDNA","IE00B19Z9Z06.USD","LU0061475181.USD","LU2362541273.HKD","LU2324357040.USD","SG9999013999.USD","LU2462157665.USD","LU1093756168.USD","VERX","BK4588","BK4533","LU0566484027.USD","LU0234570918.USD","LU1069344957.HKD","SG9999001176.USD","GNMX","VRTX","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658130309","title":"U.S. Stocks on the MOVE-Duke Energy, Sea, Cardinal Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2658130309","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658130309?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:21","pubTimestamp":1786454464,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal HealthAugust 11 (Reuters)-Wall Street's main indexes were poised to open higher on Tuesday as investors welcomed a report suggesting the United ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL6N4480DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0499858602.USD","SG9999013460.SGD","IE00BJT1NW94.SGD","ASTX","LU1621767810.EUR","LU0072461881.USD","LU2290526834.HKD","LU1242518931.SGD","LU0289960550.SGD","LU1323610961.USD","FUTY","BK4213","LU2065171311.SGD","LU0889565916.HKD","BK4187","LU2008162690.USD","BK4181","LU2065171402.SGD","URAN","SG9999006266.SGD","XITK","BBH","ACIU","BK4141","LU0640476718.USD","LU0499858438.USD","LU1242518857.USD","VPU","XLU","BK4585","FDNI","ASTS","SG9999001440.SGD","RKLX","LU1861217088.USD","BK4535","WBTN","LU0320765992.SGD","TTWO","HMYY","BK4547","HIYY","IE0001KFT4U8.USD","SG9999002406.SGD","CWVX","LU0441851309.USD","BNGE","LU0310800965.SGD","LTL","LU0289961442.SGD","ONON","UPW","CRWV","GLAM","BK4505","BK4023","LU2065170008.USD","LU1861559042.SGD","LU2384288077.EUR","BK4212","LU0823038988.USD","BK4089","IE0009355771.USD","LU0082616367.USD","LU2362540622.SGD","AIS","LU1804176565.USD","LU0516423174.USD","LU1244550494.USD","LU0737861269.HKD","NET","VG","BK4218","LU0061475181.USD","LU0154236417.USD","LU0162691827.USD","BK4524","CRWU","BK4116","LU1861220207.SGD","LU2362541513.USD","CORD","NURE","GAP","LU0823039010.USD","LU1244550577.SGD","LU2238330802.EUR","IDU","LU0072462343.USD","BK4564","CAH","HIMZ","SG9999005177.SGD","LU0210637038.USD","IE00BJJMRZ35.SGD","LU0516422440.USD","ORBX","BK4225","JAN","LU0589944569.HKD","LU1880398554.USD","BK4613","LU1880398471.USD","SG9999002950.SGD","CANC","MEMS","BK4606","BK4554","BK4560","JXI","LU1983299246.USD","IE000M9KFDE8.USD","SG9999013478.USD","BK4588","MARS","LU2362541273.HKD","LU1571399168.USD","LU2125910849.SGD","BK4551","LU2286300806.USD","IE00B29SXL02.USD","BK4526","LU0289739343.SGD","LU1430594728.SGD","SGXZ58947870.SGD","LU2360107168.USD","LU0274383776.USD","LU2152927971.USD","LU1861220033.SGD","SG9999001135.SGD","LU2125910500.SGD","DIPR","NETX","LU2463526074.USD","LU0532188223.SGD","BK4566","LU0048573645.USD","LU0345775950.USD","LU2543165471.USD","LU0006061336.USD","LU0175139822.USD","LU0572940350.SGD","IE0002141913.USD","PTH","LU0251143029.SGD","LEGN","LU1048588211.SGD","BK4081","HIMS","LU0057025933.USD","FSPC","BYND","ASTN","LU0511384066.AUD","LU0310799852.SGD","LU2360107671.USD","SG9999002679.SGD","XDAT","TRUU","NERD","LU1621768206.USD","BK4581","LU0979878070.USD","IDNA","BK4503","LU2089985449.USD","RHP","UFO","WSPC","CLOU","LU2065169927.USD","SG9999002604.SGD","BK4077","BK4607","LU1267930227.SGD","LU0516422366.SGD","LU1839390173.USD","BK4548","LU0211328371.USD","SG9999014492.USD","WARP","LU0264606111.USD","LU0472753341.HKD","DUK","CRWG","BK4094","LU1280957306.USD","LU1621768115.EUR","RVMD","SG9999004360.SGD","IE00B29SXK94.USD","LU0081259029.USD","XLC","LU1244550221.USD","FPWR","LU0128525689.USD","LU1267930490.SGD","LU0572939691.SGD","LU1621767737.EUR","WTRE","BK4120","HEAL","LU0211327993.USD","LU1585245621.USD","HIMY","CWII","LU0719512351.SGD","IE0031814969.USD","LU0109394709.USD","LU2045819591.USD","LU0889566641.SGD","LU1861215975.USD","BK4007","RSPC","RKLZ","RKLB","BSP","SG9999014484.SGD","BK4220","MEDI","SFD","LU0792757196.USD","SG9999002414.USD","BK4196","BK4085","IE00B2B36J28.USD","BK4139","BK4146","LU0052756011.USD","LU0516422952.EUR","LU0345776255.USD","NUKX","STTK","IE0034224299.USD","IE00B4R5TH58.HKD","BK4615","LU0516423091.SGD","SG9999013486.USD","FXG","THNR","HERO","UAA","NETG","SE","SIMO","IE0009354923.USD","ESPO","LU1770036033.HKD","LU2177674079.SGD","LU1861558580.USD","IE00BD6J9T35.USD","LU2265009873.SGD","SG9999002620.SGD","LU0261945553.USD","LU0069063385.USD","BK4175","AHR","LU0348788117.USD","BK4202","IE00BFTCPJ56.SGD","LU1267930813.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658194913","title":"Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition","url":"https://stock-news.laohu8.com/highlight/detail?id=2658194913","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658194913?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:05","pubTimestamp":1786453500,"startTime":"0","endTime":"0","summary":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342811/0/en/longeveron-named-a-finalist-team-and-will-receive-a-1-000-000-milestone-2-award-for-the-xprize-healthspan-global-competition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","NVIB","IDNA","BK4132","BK4120","MSC","BK4150","BK4575","MEDX","AD","GDOC","BK4139","TISI","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658913504","title":"Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658913504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658913504?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:00","pubTimestamp":1786453226,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-ge-healthcare-technologies-inc-gehc-vertex-pharmaceuticals-vrtx-and-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-ge-healthcare-technologies-inc-gehc-vertex-pharmaceuticals-vrtx-and-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002270589.USD","LU1261432733.SGD","LU2756315664.SGD","BK4532","GE","GNMX","EXI","TBXU","LU0417517546.SGD","PPA","LU0058720904.USD","LU1559883803.SGD","LU2417539215.USD","LU0757428866.USD","BIB","LU0157215616.USD","XLV","XBI","METV","NATO","MISL","BBH","PBE","LU2756315318.SGD","TRUI","IBBQ","AGIO","IE0009355771.USD","LU2089984988.USD","BK4588","ITA","LU1093756325.SGD","UXI","IE00B19Z9P08.USD","LGHT","LU0267386448.USD","GEHC","XAR","LU0353189680.USD","SG9999001176.SGD","VERX","VRTX","BK4139","IBB","DFEN","IDNA","LU1084165304.USD","LU0820561909.HKD","LABU","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658918451","title":"Vertex Pharmaceuticals Incorporated : Bofa Global Research Adds Stock to Its US 1 List","url":"https://stock-news.laohu8.com/highlight/detail?id=2658918451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658918451?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:47","pubTimestamp":1786452456,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN448154:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4533","LU0109394709.USD","SG9999001176.USD","LU2237438978.USD","BIB","LU1585245621.USD","LU0256863811.USD","LU1035775433.USD","LU0289739699.SGD","IBBQ","VRTX","LU0079474960.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU2417539215.USD","TBXU","BBH","LU0234570918.USD","IE00BJT1NW94.SGD","IE00B19Z9Z06.USD","LU2089984988.USD","LU1430594728.SGD","BK4567","LU0823416689.USD","IE0009355771.USD","IDNA","IE00BZ9MQY76.HKD","SG9999013999.USD","IE00BFTCPJ56.SGD","IE0002270589.USD","LU0058720904.USD","BK4588","LU0061475181.USD","LU0889565916.HKD","LU2324357040.USD","GNMX","LU2362541513.USD","LU1674673428.USD","LU2462157665.USD","SGXZ57979304.SGD","PBE","BK4139","LU1093756168.USD","LU1093756325.SGD","IE00B19Z9P08.USD","LU0417517546.SGD","SG9999001176.SGD","LU2468319806.SGD","LU1778281490.HKD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658399001","title":"PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101","url":"https://stock-news.laohu8.com/highlight/detail?id=2658399001","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658399001?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:25","pubTimestamp":1786451100,"startTime":"0","endTime":"0","summary":"PDS0301 Phase 2 clinical data in mCRC and a comprehensive review of capital allocation priorities drive strategic refocus designed to maximize long-term shareholder valuePRINCETON, N.J., Aug.  11, 202","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342690/37149/en/pds-biotech-announces-strategic-refocus-prioritizing-pds0301-in-metastatic-colorectal-cancer-mcrc-and-partnership-strategy-for-pds0101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MSS","BK4092","ORR","BK4581","PDS","IDNA","XBI","BK4585","BK4113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658099084","title":"Press Release: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658099084","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658099084?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:01","pubTimestamp":1786449660,"startTime":"0","endTime":"0","summary":"reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment. -- New manufacturing batch completed including process enhancements that. have further reduced already low levels of process impurities.-- Kalaris is currently conducting a Phase 1b/2, multi-ascending dose,The study aims to assess the safety and efficacy of repeat doses of TH103. at different dose levels and to identify the optimal dose and regimen for. potential Phase 3 development. Preliminary data from the Phase 1b/2 study. is expected in the first half of 2027.-- As previously announced, Kalaris expanded its leadership team with the. hire of Liisa Bayko as Chief Financial Officer. Ms. Bayko brings more. than two decades of experience in biotechnology finance, strategy, and. capital markets, most recently serving as Managing Director and Senior. Biotechnology Analyst at Evercore ISI, where she was consistently. recognized as one of the industry's top-ranked analysts covering small-. -- As announced recently, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","GDOC","IDNA","HYLG","MEDX","NVIB","BK4139","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990407","title":"IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990407","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990407?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Pha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342668/0/en/imunon-reports-second-quarter-2026-financial-results-and-provides-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","GDOC","BK4139","NVIB","HYLG","IDNA","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990336","title":"Press Release: Theriva(TM) Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990336?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"Phase 2a clinical trial entitled \"A Phase IIa, single-arm, single-center,-- The VIRAGE2 study design incorporates feedback from both the. European Medicines Agency  and the U.S. Food and Drug. VIRAGE Phase 2b trial in metastatic PDAC patients treated with 2. repeated dosing of VCN-01 may provide additional clinical benefit.-- The VIRAGE2 trial will evaluate the safety and feasibility of. administering at least 3 doses of VCN-01 given approximately 2. The trial is expected to enroll 6 evaluable patients. Results from. the VIRAGE2 study will inform the VCN-01 dosing regimen for","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4081","NVIB","IDNA","LU0053666078.USD","TOVX","BK4139","03160","LU0210528500.USD","BK4588","BK4604","BK4555","BK4099","GDOC","BK4107","MEDX","EMA","HYLG","LU2487616109.SGD","L","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658447990","title":"Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658447990","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658447990?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in c","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342635/0/en/kalaris-reports-second-quarter-2026-financial-results-and-provides-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","GDOC","MEDX","BMED","IDNA","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658528997","title":"Truist Raises Revolution Medicines PT on Lung Cancer Pipeline Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2658528997","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658528997?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:41","pubTimestamp":1786448509,"startTime":"0","endTime":"0","summary":"BUZZ-Truist raises Revolution Medicines PT on lung cancer pipeline potential** Brokerage Truist Securities raises price target for Revolution MedicinesRVMD.Oto $231 from $210** Maintains \"buy\" rating** Says recent advancement of elironrasib and zoldonrasib into late-stage studies in first-line non-small cell lung cancer  strengthens RVMD's position in RAS-targeted cancers** Sees both programs expanding RVMD's addressable market in lung cancer and supporting a more diversified RAS franchise**The new price target represents a 11.6% upside to the stock's last close** Brokerage continues to expect potential approval ofdaraxonrasibin previously treated pancreatic cancer in Q3 2026** \"While pricing remains an open question, mgmt expressed confidence that organizational, market access, patient-support and distribution capabilities will not be limiting factors\" - Truist says** As of last close, stock has more than doubled YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4N4480SP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BBH","IE00BFTCPJ56.SGD","IDNA","IE0009355771.USD","CANC","LU0320765992.SGD","IE00B4R5TH58.HKD","PTH","IE0009354923.USD","IE0002141913.USD","BK4139","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0889565916.HKD","IE00B2B36J28.USD","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992080","title":"Press Release: Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992080","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992080?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":"advance denifanstat in moderate to severe acne for the U.S., prioritizing. -- Equity financing: In April 2026, the Company completed an underwritten. equity financing resulting in $175.0 million of gross proceeds, before. deducting underwriting discounts and commissions and other offering. -- Russell Index inclusion: Sagimet was added to the broad-market Russell. 3000 Index and small-cap Russell 2000 Index effective June 29,-- TVB-3567: A first-in-human Phase 1 clinical trial of FASN inhibitor. -- KOL event: On April 30, 2026, the Company hosted a Key Opinion Leader. event with Julie Harper, MD, founding Director and past President of. the American Acne and Rosacea Society, discussing the acne treatment. landscape and Sagimet's planned Phase 3 clinical trial. A recording of. the event is accessible at this link.Publications and Presentations-- Data showing that Sagimet's FASN inhibitors reduced de novo lipid levels. in human sebocytes were presented at the 83rd Society for Investigativ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","BK4232","IDNA","BK4139","SGMT","R","BK1145","00511","NVIB","MEDX","HYLG","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658799280","title":"Press Release: Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658799280","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658799280?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446000,"startTime":"0","endTime":"0","summary":"directly targeting the underlying sarcomeric defects in genetic dilated. --  Danicamtiv is currently being evaluated in the Company's KINSHIP-DCM. --  Preclinical and clinical evidence linking danicamtiv treatment to. improvements in right ventricular function to be presented at the. upcoming European Society of Cardiology Congress . [Session:. Late-Breaking Basic and Translational Science; Sunday, Aug. 30th at 8:15. --  In July, the Company completed enrollment of Cohort 1 (myosin heavy. chain 7, or MYH7, and titin, or TTN, patients) of the Phase 2b. KINSHIP-DCM clinical trial and enrollment of the Phase 3 portion is now. underway. The Company expects to share Phase 2b topline data in the first. half of 2027.Ataciguat: soluble guanylate cyclase  activator in development for CAVS--  Ataciguat targets valvular interstitial cells to slow osteogenic and. calcific remodeling, an underlying driver of disease progression in. calcific aortic valve stenosis , and has demonstrated direct. myoca","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4109","IDNA","AGT","BK4604","03160","HYLG","NVIB","ASH","BK4555","BK4585","BK4588","KARD","GDOC","TM","BK4099","MEDX","LU2463526074.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":12,"totalSize":240,"code":"91000000","status":"200"}]}}